Our review of the current knowledge about XPO1 and XPO1 inhibition in childhood cancer offers an enthusiastic outlook about the potential for integrating XPO1-directed therapy as part of combination treatment to improve outcomes for children with highly aggressive malignancies. The gene discussed is XPO1; the disease is childhood malignant neoplasm.